• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[¹⁸F-FDG PET/CT在初诊弥漫性大B细胞淋巴瘤骨髓浸润中的诊断及预后价值]

[Diagnostic and Prognostic Value of F-FDG PET/CT in Bone Marrow Infiltration of Newly Diagnosed Diffuse Large B-Cell Lymphoma].

作者信息

Chen Xiang, Qiao Wen-Li, Song Jian-Hua, Liu Chang-Cun, Han Lei, Wu Shan, Zhao Jin-Hua

机构信息

Clinical Medical College of Shanghai General Hospital of Nanjing Medical University, Shanghai 200080, China.

Clinical Medical College of Shanghai General Hospital of Nanjing Medical University, Shanghai 200080, China. E-mail:

出版信息

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Aug;31(4):1044-1049. doi: 10.19746/j.cnki.issn.1009-2137.2023.04.018.

DOI:10.19746/j.cnki.issn.1009-2137.2023.04.018
PMID:37551475
Abstract

OBJECTIVE

To explore the diagnostic value of F-FDG PET/CT in bone marrow infiltration (BMI) of newly diagnosed diffuse large B-cell lymphoma (DLBCL), compared with the results of bone marrow biopsy (BMB) and investigate whether the BMI diagnosed by F-FDG PET/CT and other factors have independent prognostic values.

METHODS

Ninety-four newly diagnosed DLBCL patients who underwent PET/CT in Clinical Medical College of Shanghai General Hospital of Nanjing Medical University were included. BMB was performed within 2 weeks before or after PET/CT, and standardized treatment was performed after PET/CT. The manifestations of bone marrow (BM) FDG uptake were recorded. The diagnostic criteria of BMI were BMB positive or focal BM FDG uptake confirmed by imaging follow-up. The relationship between clinical features and BM FDG uptake and the values of PET/CT and BMB in the diagnosis of BMI was analyzed. The progression-free survival (PFS) was analyzed by Kaplan-Meier survival curves, log-rank test was used to compare PFS rate, and Cox regression model was used to analyze the independent risk factors affecting PFS.

RESULTS

Among 94 DLBCL patients, 34 patients showed focal BM uptake (fPET), 7 patients showed super BM uptake (sBMU), 11 patients showed diffuse homogenous uptake higher than liver (dPET), and the other 42 patients had normal BM uptake (nPET) (lower than liver). BMB positive was found in all sBMU patients, in 20.6%(7/34) of fPET patients, and in 27.3% (3/11) of dPET patients. All nPET patients had negative BMB results. dPET patients were associated with lower hemoglobin level and leukocyte count compared with nPET group ( < 0.001, =0.026). Compared with fPET patients, sBMU patients were more likely to have B symptoms and elevated lactate dehydrogenase (LDH). A total of 44 patients were diagnosed BMI, including 17 cases with BMB. The sensitivity and specificity of BMB in the diagnosis of BMI was 38.6% (17/44) and 100% (50/50), respectively. Using fPET and sBMU as criteria of PET BMI, the diagnostic sensitivity and specificity of PET/CT was 93.2% (41/44) and 100% (50/50), respectively. Kaplan-Meier analysis showed that there was no significant difference in 2-year PFS rate between nPET and dPET patients ( >0.05), while sBMU patients had lower 2-year PFS rate compared with fPET patients ( < 0.001). Multivariate analysis showed that higher Ann Arbor stage (=9.010, =0.04) and sBMU (=3.964, =0.002) were independent risk factors affecting PFS.

CONCLUSIONS

Increased BM FDG uptake of DLBCL can be manifested as dPET, fPET and sBMU. fPET and sBMU can replace BMB to diagnose BMI. Although dPET cannot completely exclude the possibility of BMI, it does not affect the prognosis, so it can be diagnosed as PET BMI negative. sBMU is an independent prognostic risk factor.

摘要

目的

探讨¹⁸F-FDG PET/CT在初诊弥漫性大B细胞淋巴瘤(DLBCL)骨髓浸润(BMI)中的诊断价值,并与骨髓活检(BMB)结果进行比较,同时研究¹⁸F-FDG PET/CT诊断的BMI及其他因素是否具有独立预后价值。

方法

纳入南京医科大学附属上海第一人民医院临床医学院94例接受PET/CT检查的初诊DLBCL患者。在PET/CT检查前后2周内进行BMB,并在PET/CT检查后进行标准化治疗。记录骨髓(BM)¹⁸F-FDG摄取表现。BMI的诊断标准为BMB阳性或经影像学随访证实的局灶性BM¹⁸F-FDG摄取。分析临床特征与BM¹⁸F-FDG摄取的关系以及PET/CT和BMB在BMI诊断中的价值。采用Kaplan-Meier生存曲线分析无进展生存期(PFS),用对数秩检验比较PFS率,用Cox回归模型分析影响PFS的独立危险因素。

结果

94例DLBCL患者中,34例表现为局灶性BM摄取(fPET),7例表现为超BM摄取(sBMU),11例表现为弥漫性均匀摄取高于肝脏(dPET),其余42例BM摄取正常(nPET)(低于肝脏)。所有sBMU患者BMB阳性,fPET患者中有20.6%(7/34)BMB阳性,dPET患者中有27.3%(3/11)BMB阳性。所有nPET患者BMB结果为阴性。与nPET组相比,dPET患者血红蛋白水平和白细胞计数较低(P<0.001,P =0.026)。与fPET患者相比,sBMU患者更易出现B症状和乳酸脱氢酶(LDH)升高。共44例患者诊断为BMI,其中17例经BMB确诊。BMB诊断BMI的敏感性和特异性分别为38.6%(17/44)和100%(50/50)。以fPET和sBMU作为PET BMI标准,PET/CT的诊断敏感性和特异性分别为93.2%(41/44)和100%(50/50)。Kaplan-Meier分析显示,nPET和dPET患者2年PFS率无显著差异(P>0.05),而sBMU患者2年PFS率低于fPET患者(P<0.001)。多因素分析显示,较高的Ann Arbor分期(P =9.010,P =0.04)和sBMU(P =3.964,P =0.002)是影响PFS的独立危险因素。

结论

DLBCL的BM¹⁸F-FDG摄取增加可表现为dPET、fPET和sBMU。fPET和sBMU可替代BMB诊断BMI。虽然dPET不能完全排除BMI的可能性,但不影响预后,可诊断为PET BMI阴性。sBMU是独立的预后危险因素。

相似文献

1
[Diagnostic and Prognostic Value of F-FDG PET/CT in Bone Marrow Infiltration of Newly Diagnosed Diffuse Large B-Cell Lymphoma].[¹⁸F-FDG PET/CT在初诊弥漫性大B细胞淋巴瘤骨髓浸润中的诊断及预后价值]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Aug;31(4):1044-1049. doi: 10.19746/j.cnki.issn.1009-2137.2023.04.018.
2
[Prognostic value of bone marrow (18)F-FDG uptake pattern of pretreatment PET-CT in extranodal NK/T cell lymphoma].[治疗前PET-CT骨髓(18)F-FDG摄取模式在结外NK/T细胞淋巴瘤中的预后价值]
Zhonghua Zhong Liu Za Zhi. 2020 Oct 23;42(10):885-890. doi: 10.3760/cma.j.cn112152-20191115-00739.
3
[The Value of Baseline PET/CT Imaging of Bone Marrow F-FDG Uptake Pattern in Predicting Prognosis of DLBCL].[骨髓F-FDG摄取模式的基线PET/CT成像在预测弥漫性大B细胞淋巴瘤预后中的价值]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Apr;32(2):439-444. doi: 10.19746/j.cnki.issn.1009-2137.2024.02.018.
4
Prognostic Value of Bone Marrow FDG Uptake Pattern of PET/CT in Newly Diagnosed Diffuse Large B-cell Lymphoma.PET/CT检查中骨髓FDG摄取模式对初诊弥漫性大B细胞淋巴瘤的预后价值
J Cancer. 2018 Mar 14;9(7):1231-1238. doi: 10.7150/jca.23714. eCollection 2018.
5
In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.在新诊断的弥漫性大 B 细胞淋巴瘤中,与活检相比,18F-FDG PET/CT 检测骨髓累及可提供更好的诊断性能和预后分层。
J Nucl Med. 2013 Aug;54(8):1244-50. doi: 10.2967/jnumed.112.114710. Epub 2013 May 14.
6
Prognostic Importance of Bone Marrow Uptake on Baseline F-FDG Positron Emission Tomography in Diffuse Large B Cell Lymphoma.弥漫性大B细胞淋巴瘤患者基线F-FDG正电子发射断层扫描骨髓摄取的预后意义
Cancer Biother Radiopharm. 2016 Dec;31(10):361-365. doi: 10.1089/cbr.2016.2132.
7
Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.骨髓 18F-氟代-2-脱氧-D-葡萄糖正电子发射断层扫描/计算机断层扫描不能替代弥漫性大 B 细胞淋巴瘤的骨髓活检。
Am J Hematol. 2014 Jul;89(7):726-31. doi: 10.1002/ajh.23730. Epub 2014 Apr 18.
8
Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study.基线 PET 扫描中骨髓示踪剂摄取模式对霍奇金淋巴瘤的预后价值:一项国际合作研究的结果。
J Nucl Med. 2017 Aug;58(8):1249-1254. doi: 10.2967/jnumed.116.184218. Epub 2017 Jan 26.
9
Diagnosis of bone marrow involvement in angioimmunoblastic T-cell lymphoma should be based on both [F]FDG-PET/CT and bone marrow biopsy findings.诊断血管免疫母细胞性 T 细胞淋巴瘤骨髓累及应基于 [F]FDG-PET/CT 和骨髓活检结果。
Curr Med Res Opin. 2024 May;40(5):803-811. doi: 10.1080/03007995.2024.2337670. Epub 2024 Apr 16.
10
Detection performance and prognostic value of initial bone marrow involvement in diffuse large B-cell lymphoma: a single centre F-FDG PET/CT and bone marrow biopsy evaluation study.弥漫大 B 细胞淋巴瘤初始骨髓侵犯的检出性能和预后价值:一项单中心 F-FDG PET/CT 和骨髓活检评估研究。
Radiol Oncol. 2024 Feb 21;58(1):15-22. doi: 10.2478/raon-2024-0004. eCollection 2024 Mar 1.